Solé, LauraLobo-Jarne, TeresaCabré-Romans, Júlia-JiéGonzález, AntónFernández, LierniMarruecos, LauraGuix Arnau, Marta, 1974-Cuatrecasas, MiriamLópez Prades, SandraBellosillo Paricio, BeatrizTorres, FerranIglesias Coma, MarBigas Salvans, AnnaEspinosa Blay, Lluís2024-10-012024-10-012024Solé L, Lobo-Jarne T, Cabré-Romans JJ, González A, Fernández L, Marruecos L, et al. Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients. Biochim Biophys Acta Mol Cell Res. 2024 Mar;1871(3):119658. DOI: 10.1016/j.bbamcr.2024.1196580167-4889http://hdl.handle.net/10230/61278Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1. Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients. Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse. Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.application/pdfeng© 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.1016/j.bbamcr.2024.119658CDX1Colorectal cancerFetal conversionPatient prognosisinfo:eu-repo/semantics/openAccess